MG
GRNA

Michael Gelband’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Michael Gelband’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42,231
Closed -$407K – 2643
2022
Q1 		$407K Buy
+42,231
New +$378K 0.01% 1643

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
VS
VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return
CGC
Continental Grain Company New York $448M AUM 6.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's GRNA Position: Q2 2022 in Review

Michael Gelband sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2022, closing a stake of 42,231 shares — an estimated $407K sold.

Michael Gelband first reported a position in GRNA in Q1 2022 and held it in 1 quarter. The position peaked at $407K in Q1 2022. 50 funds tracked by Wall St. Rank hold GRNA as of Q2 2022.

  • Michael Gelband reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 42,231 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2022, an estimated $407K.
  • Michael Gelband first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 1 quarter.
  • Michael Gelband's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $407K in Q1 2022.
  • 50 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.